HOME >> MEDICINE >> NEWS
Therapy for mice with prion disease could offer benefit to human beings with CJD

Authors of a fast-track research letter in this week's issue of THE LANCET describe a therapeutic treatment which increased the survival time for mice with prion disease. These results could represent a new approach to treating CJD in human beings.

The lack of an immune response to prions--the infectious proteins that cause scrapie, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease (CJD)--might be related to the fact that these agents do not contain nucleic acids (genetic material).

Hans Kretzschmar from Ludwig-Maximilians University and colleagues from the Technical University Munich, Germany, and Coley Pharmaceuticals, aimed to use genetic material (a specific type of nucleotide arrangement called CpG oligodeoxynucleotides) as a form of disease treatment after prion infection in mice. CpG oligodeoxynucleotides have previously been shown to stimulate the immune response.

The investigators inoculated 24 healthy mice with brain extracts from mice infected with scrapie prions, and then injected CpG oligodeoxynucleotides. This procedure resulted in 38% longer survival times than a control group that were injected with saline solution; longer survival times occurred when CpG oligodeoxynucleotides were given repeatedly over a three-week period.

Hans Kretzschmar comments: "The most likely explanation is the stimulation of TLR9-expressing cells of the innate immune system such as macrophages, monocytes, and dendritic cells. CpG oligodeoxynucleotides have not been shown to have adverse effects to human health and could therefore be considered as a therapeutic choice after prion infection."

In an accompanying Commentary (p 184), George Carlson from the McLaughlin Research Institute, USA, states that the approach of Kretzschmar and colleagues is reasonable, and concludes: "Development of improved diagnostics and postexposure prophylaxis are urgently needed given the unknown prevalence of subclinical prion infecti
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
18-Jul-2002


Page: 1 2

Related medicine news :

1. UT Southwestern Moncrief Cancer Center is first in Texas to treat patients with TomoTherapy
2. Therapy, medication combination superior for children with obsessive-compulsive disorder
3. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
4. Vagus Nerve Stimulation Therapy (TM) more effective in epilepsy patients when used earlier
5. Therapy to help women reduce their concerns about gaining weight found to be effective in helping them to stop smoking
6. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
7. UCSF Study Shows That An Herbal Therapy Reduces PSA Levels By Half In Men With Advanced Prostate Cancer
8. Sniffing Out The Promise Of Anti-Angiogenesis Therapy
9. Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia
10. Jefferson Researchers Report First Evidence Of Radiation Therapy Preventing Prostate Cancer Patients From Dying
11. Combination Therapy Improves Chances Of Surviving Esophageal Cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Torrance dentist, ... aesthetics can be one of the most noticeable aspects of a person’s appearance. A ... not everyone is born with beautiful, balanced teeth, everyone can have the smile of ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin ... Specialists, in collaboration with the Fertility Center of California, is pleased to announce ... epidydimal sperm aspiration) and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments ...
(Date:6/26/2017)... ... June 26, 2017 , ... ... recent review of government data released by the United Soybean Board. , ... Maryland’s soybean farmers have increased their productivity on less land per bushel, the ...
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative ... in every state across the country to join its online treatment platform. , ... therapists to reach a substantially greater number of people in need nationwide, and to ...
(Date:6/26/2017)... ... 26, 2017 , ... KICKICO , a protocol built on Ethereum for ... many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, which will ... the raising of funds through the power of many - has been around for ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)...  In 2016, Embodied Labs took top ... and came away with $25,000 in seed-fund investment. Embodied ... as "entering the life of another" and by the ... to medical professionals in an entirely new dimension." Building ... finalist for the Department of Education,s EdSimChallenge, where they ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/9/2017)... and INDIANAPOLIS , June ... are living with diabetes. In a further effort to ... people affected by this condition, the International Diabetes Federation ... LLY ) have come together for the second phase ... and Systems programme (BRIDGES 2), reaffirming their commitment to ...
Breaking Medicine Technology:
Cached News: